Journal of Diabetic Complications & Medicine

Background: Disturbance in renal function was considered to be a common complication of Cyclosporine-A (CsA) treated patients of recent-onset type 1 diabetes mellitus, for purposes of remission. The aim of the present study was to scrutinize the potential association between this drug and its complications by conducting a meta-analysis of randomized control trials.

Methods: A consummate literature search of PubMed, EMBASE, and web of science was conducted until March 2019. A total of 9 randomized control trials were included in this meta-analysis.

Results: On meta-analysis of nine studies evaluating the risk of transient complications, analysis of the random effect of 12 months-low dose-cyclosporine on serum creatinine, revealed the absence of CsA induced nephrotoxicity. And no association between CsA and renal function in newly diagnosed type 1 diabetic patients Odds Ratio (OR), 1.06; 95% Confidence Interval (CI), 1.00-1.43; I²=73.1%). No noteworthy publication bias was noticed in the designated 9 studies.

Conclusion: 12 months low dose CsA was not associated with risk of deterioration of renal function according to the results revealed from the meta-analysis of RCTs which is considered as the summit of the research pyramid.

Diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose levels, has reached epidemic proportions globally. With its rising prevalence and profound impact on health, extensive research efforts have been dedicated to understanding, managing and preventing diabetes. Over the years, significant progress has been made in diabetes research and clinical practice, leading to improved diagnostic tools, therapeutic strategies and lifestyle interventions. This article aims to shed light on recent advancements in diabetes research and their potential implications for clinical practice.